风湿病继发骨质疏松症研究进展
赵东宝 . 风湿病继发骨质疏松症研究进展[J]. 内科理论与实践, 2022 , 17(03) : 181 -185 . DOI: 10.16138/j.1673-6087.2022.03.001
| [1] | George S, Aline B. Osteoimmunology[M]//Marc CH, Alan JS, Josef SS, et al. Rheumatology. 6th ed. Philadelphia, USA: Elsevier Mosby, 2015: 165-168. |
| [2] | Horton JE, Raisz LG, Simmons HA, et al. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes[J]. Science, 1972, 177(4051): 793795. |
| [3] | Mundy GR, Luben RA, Raisz LG, et al. Bone-resorbing activity in supernatants from lymphoid cell lines[J]. New Engl J Med, 1974, 290(16): 867-871. |
| [4] | Srivastava RK, Dar HY, Mishra PK. Immunoporosis: immunology of osteoporosis-role of T cells[J]. Front Immunol, 2018, 9: 657. |
| [5] | Ke K, Sul OJ, Chung SW, et al. Lack of NOD2 attenuates ovariectomy-induced bone loss via inhibition of osteoclasts[J]. J Endocrinol, 2017, 235(2): 85-96. |
| [6] | Souza PPC, Lerner UH. Finding a Toll on the route: the fate of osteoclast progenitors after Toll-like receptor activation[J]. Front Immunol, 2019, 10: 1663. |
| [7] | Plotkin LI, Essex AL, Davis HM. RAGE signaling in skeletal biology[J]. Curr Osteoporos Rep, 2019, 17(1): 16-25. |
| [8] | Karner CM, Long F. Glucose metabolism in bone[J]. Bone, 2018, 115: 2-7. |
| [9] | Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo[J]. J Immunol, 2008, 181(2):1232-1244. |
| [10] | Huang R, Wang X, Zhou Y, et al. RANKL-induced M1 macrophages are involved in bone formation[J]. Bone Res, 2017, 5: 17019. |
| [11] | Dou C, Ding N, Zhao C, et al. Estrogen deficiency-mediated M2 macrophage osteoclastogenesis contributes to M1/M2 ratio alteration in ovariectomized osteoporotic mice[J]. J Bone Miner Res, 2018, 33(5): 899-908. |
| [12] | Omata Y, Frech M, Primbs T, et al. Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice[J]. Cell Rep, 2018, 24(1):169-180. |
| [13] | Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature, 1999, 402(6759): 304-309. |
| [14] | Pugliese LS, Gonçalves TO, Popi AF, et al. B-1 lymphocytes differentiate into functional osteoclast-like cells[J]. Immunobiology, 2012, 217(3): 336-344. |
| [15] | Fujiwara Y, Piemontese M, Liu Y, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients[J]. J Biol Chem, 2016, 291: 24838-24850. |
| [16] | Adami G, Fassio A, Rossini M, et al. Osteoporosis in rheumatic diseases[J]. Int J Mol Sci, 2019, 20(23): 5867. |
| [17] | Orsolini G, Caimmi C, Viapiana O, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients[J]. Calcif Tissue Int, 2017, 101(1): 17-23. |
| [18] | van der Weijden MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review[J]. Clin Rheumatol, 2012, 31(11): 1529-1535. |
| [19] | Gamsjaeger S, Srivastava AK, Wergedal JE, et al. Altered bone material properties in HLA-B27 rats include reduced mineral to matrix ratio and altered collagen cross-links[J]. J Bone Miner Res, 2014, 29(11): 2382-2391. |
| [20] | Kim SC, Paik JM, Liu J, et al. Gout and the risk of non-vertebral fracture[J]. J Bone Miner Res, 2017, 32(2): 230-236. |
| [21] | Ceccarelli F, Perricone C, Colasanti T, et al. Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus[J]. Arthritis Res Ther, 2018, 20(1): 126. |
| [22] | Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus[J]. Lupus, 2017, 26(4):365-372. |
| [23] | Ruaro B, Casabella A, Paolino S, et al. Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score(TBS)[J]. Clinical Rheumatol, 2018, 37(11):3057-3062. |
| [24] | Hu Z, Zhu S, Zhang B. Impaired bone health in patients with primary Sjogren’s syndrome[EB/J]. Arthritis Rheumatol, 2016. https://acrabstracts.org/abstract/impaired-bone-health-in-patients-with-primary-sjogrens-syndrome/. |
| [25] | Englund M, Merkel PA, Tomasson G, et al. Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population[J]. J Rheumatol, 2016, 43(8): 1553-1558. |
| [26] | Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials[J]. Ann Rheum Dis, 2015, 74(1): 177-184. |
| [27] | Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide[J]. Drugs Aging, 2019, 36(12): 1061-1072. |
| [28] | Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis[J]. Cochrane Database Syst Rev, 2015(4): CD005468. |
| [29] | Chen YM, Chen HH, Huang WN, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis[J]. PLoS One, 2017, 12(11): e0188454. |
| [30] | Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton[J]. Calcif Tissue Int, 2018, 102(5): 607-618. |
| [31] | Chen XD, Xiao P, Lei SF, et al. Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians[J]. J Bone Miner Res, 2010, 25(2): 339-355. |
| [32] | Zhou H, Newnum AB, Martin JR, et al. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species[J]. Bone, 2011, 49(3): 404-411. |
| [33] | Solomon DH, Kay J, Duryea J, et al. Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial[J]. Arthritis Rheumatol, 2017, 69(9): 1741-1750. |
| [34] | Yue J, Griffith JF, Xiao F, et al. Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study[J]. Arthritis Care Res (Hoboken), 2017, 69(8):1156-1163. |
| [35] | Ostrovsky V, Malnick S, Ish-Shalom S, et al. Denosumab-induced immune hepatitis[J]. Biomedicines, 2021, 9(1): 76. |
/
| 〈 |
|
〉 |
